<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613557</url>
  </required_header>
  <id_info>
    <org_study_id>CYAD-211-001</org_study_id>
    <nct_id>NCT04613557</nct_id>
  </id_info>
  <brief_title>Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <acronym>IMMUNICY-1</acronym>
  <official_title>Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celyad Oncology SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celyad Oncology SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of&#xD;
      CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion&#xD;
      regimen with fludarabine and/or cyclophosphamide&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to determine the recommended dose of the allogeneic CYAD-211 (anti-BCMA&#xD;
      CAR-T) cells after a non-myeloablative preconditioning chemotherapy in multiple myeloma (MM)&#xD;
      patients with relapsed or refractory disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 26, 2020</start_date>
  <completion_date type="Anticipated">February 2036</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Dose Limiting Toxicities</measure>
    <time_frame>Up to 36 days post-infusion.</time_frame>
    <description>Occurrence of Dose Limiting Toxicities</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Relapse/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CYAD-211</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion post preconditioning non-myeloablative chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYAD-211</intervention_name>
    <description>Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell</description>
    <arm_group_label>CYAD-211</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endoxan</intervention_name>
    <description>Preconditioning chemotherapy</description>
    <arm_group_label>CYAD-211</arm_group_label>
    <other_name>cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludara</intervention_name>
    <description>Preconditioning chemotherapy</description>
    <arm_group_label>CYAD-211</arm_group_label>
    <other_name>Fludarabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Documented diagnosis of MM with relapsed or refractory disease to at least two prior&#xD;
             MM treatment regimens which should include exposure to IMiD and PIs either alone or in&#xD;
             combination.&#xD;
&#xD;
          2. Presence of measurable disease as per International Myeloma Working Group (IMWG)&#xD;
             Response Criteria&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) below or equal 2&#xD;
&#xD;
          4. Adequate hematologic, renal, hepatic, pulmonary, and cardiac function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of clinically relevant central nervous system (CNS) pathology.&#xD;
&#xD;
          2. Autologous stem cell transplant within 12 weeks of registration or an allogeneic stem&#xD;
             cell transplant within 6 months of starting study treatment.&#xD;
&#xD;
          3. Any investigational agent within 3 weeks prior to the initiation of the&#xD;
             non-myeloablative preconditioning chemotherapy).&#xD;
&#xD;
          4. Prior systemic therapy for MM within 14 days prior to the initiation of the&#xD;
             non-myeloablative preconditioning chemotherapy.&#xD;
&#xD;
          5. Prior treatment with any BCMA-targeted therapy and which has not achieved at least a&#xD;
             partial response.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celyad Oncology Medical Monitor, MD, PhD</last_name>
    <phone>+3210394100</phone>
    <email>clinicaltrials@celyad.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taiga Nishihori</last_name>
      <phone>813-745-8156</phone>
      <email>Taiga.Nishihori@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nyu Grossman School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmad Al-Homsi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SÃ©bastien ANGUILLE, MD</last_name>
      <phone>+3238213250</phone>
      <email>sebastien.anguille@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie MEULEMAN, MD</last_name>
      <phone>+3225413237</phone>
      <email>nathalie.meuleman@bordet.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ DELTA</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dries DEEREN, MD</last_name>
      <phone>+3251237322</phone>
      <email>Dries.Deeren@azdelta.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

